Key result
Yingxin Pill improves anginal stability ~7 points over Shexiang Baoxin Pill, but reduces angina frequency less.
Why the study?
To evaluate the clinical efficacy and safety of Yingxin Pill in patients with stable angina pectoris and heart blood stasis obstruction syndrome.
Does Yingxin Pill added to conventional Western medicine improve Seattle Angina Questionnaire scores in patients with stable angina pectoris and heart blood stasis obstruction syndrome?
RCT (n=60)
single-blind (participants only)
random number table with 1:1 allocation
No
Does Yingxin Pill added to conventional Western medicine improve Seattle Angina Questionnaire scores in patients with stable angina pectoris and heart blood stasis obstruction syndrome?
Yingxin Pill combined with conventional Western medicine is non-inferior to Shexiang Baoxin Pill in improving angina symptoms, lipid profiles, and inflammatory markers in patients with stable angina pectoris.
Answers are grounded in this paper and cite their sources.
May inform symptom-specific TCM selection in stable angina; extends head-to-head RCT data on Yingxin versus Shexiang Baoxin Pill.
Objective To evaluate the clinical efficacy and safety of Yingxin Pill (YXP) in patients with stable angina pectoris (SAP) and heart blood stasis obstruction syndrome. Methods Sixty patients were randomly assigned to either the experimental group (YXP plus conventional Western medicine) or the control group (Shexiang Baoxin Pill [SBP] plus conventional Western medicine), with 30 patients in each group. Treatment lasted for 4 weeks. Outcomes included the Seattle Angina Questionnaire (SAQ), a Traditional Chinese Medicine (TCM) efficacy scale, blood lipid profiles, and inflammatory markers. The effective rate and incidence of adverse events were also compared. Results After treatment, both groups showed significant improvements in SAQ scores, TCM efficacy scale scores, lipid profiles, and inflammatory markers compared to baseline (P < 0.05). There were no significant differences between the two groups in these outcomes, nor in the total effective rate or incidence of adverse events (P > 0.05). Conclusion The addition of YXP to conventional therapy can improve symptoms, reduce blood lipid and inflammation levels, and is safe for patients with SAP and heart blood stasis obstruction syndrome. Clinical Trial Registration https://itmctr.ccebtcm.org.cn/ , identifier ITMCTR2025000274.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2026) conducted an RCT in Adults aged 18-85 with stable angina pectoris and heart blood stasis obstruction syndrome of Canadian Cardiovascular Society angina class II-III (n=60). Yingxin Pill (YXP) plus conventional Western medicine vs. Shexiang Baoxin Pill (SBP) plus conventional Western medicine was evaluated on Change in Seattle Angina Questionnaire (SAQ) domain scores at 4 weeks from baseline. Yingxin Pill combined with conventional therapy improved anginal stability more than Shexiang Baoxin Pill, while Shexiang Baoxin Pill improved angina frequency more than Yingxin Pill, with no significant differences in other SAQ domains after 4 weeks in patients with stable angina pectoris and heart blood stasis obstruction syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: